Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников

37. Plant, J.A., Turner, K.T., and Highley, D.E., 1998. Minerals and the environment. Proceedings of Minerals ^c98 Conference, June 1998: Republished in the Mineralogical Society Bulletin, No. 119, July 1998, 3-11; Mineral Planning 77, December 1998, 3–8; IM&M Journal, December 1998, 1, 12, 331–336.

38. Kushi L.H. and others, 2007. Lifestyle factors and survival in women with breast cancer. The Journal of Nutrition, Special supplement; Intern. Research conf. on food, nutrition and cancer, 236S-242S.

39. Getz, Linn, Sigurdsson, Johann A. and Hetlevik, Irene, 2003. Is opportunistic disease prevention in the consultation ethically justifiable? BMJ, 327, 498.

40. Research muddled by political pressures. The Times (Public Agenda), 19 August 2003.

41. Chaturvedi, P., 2003. Medical community may be partly responsible for cancer misery. BMJ, 326, 1146.

42. Kmietowicz, Zosia, 2002. Research spending on cancers doesn’t match their death rates. BMJ, 325, 920.

43. Smith, Richard, 2003. Do patients need to read research? BMJ, 326, 3307.

44. Smith, Richard, 2003. Do patients need to read research? BMJ, 326, 1307.

45. Corrie, Pippa, Shaw, Justin and Harris, Roy, 2003. Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. BMJ, 327, 320–321.

46. Wald, Nicholas J. and Morris, Joan K… 2003. Teleoanalysis: combining data from different types of study. BMJ, 327, 616–618.

47. The Times (Public Agenda), 6 March 2007.

48. Smith, Richard, 2003. Editor’s choice: The screening industry. BMJ, 326,26 April 2003.

49. Lechin, Fuard and others, 2002. N euro circuitry and Neuroauto-nomic Disorders. Karger.

50. Gottlieb, Scott, 2003. US drug sales continue to rise. BMJ, 326, 518.

51. Gottlieb, Scott, 2002. Drug companies maintain ‘astounding’ profits, BMJ, 324, 1054.

52. Kjaergard, Lise L. and Als-Nielsen, Bodily 2002. Association between competing interests and authors’ conclusions: epide-miological study of randomised clinical trials published in the BMJ. BMJ, 325, 249–252.

53. Eaton, Lynn, 2003. Readers want transparency in link between doctors an drug firms. BMJ, 326, 1352.

54. Mayor, Susan, 2002. Researchers claim clinical trials are reported with misleading statistics. BMJ, 324, 1353.

55. JAMA, 2003, 389, 454–465, quoted by Hopkins Tanne, Janice, 2003. Industry is deeply involved in funding US research. BMJ, 326, 179.

56. Tonks, Alison, 2002. Authors of guidelines have strong links with drugs industry. BMJ, 324, 383.

57. Spurgeon, David, 2002. Doctors accept $50 a time to listen to drug representatives. BMJ, 324, 1113.

58. Gottlieb, Scott, 2003. A fifth of Americans contact their doctor as a result of direct to consumer drug advertising. BMJ, 325, 854.

59. BMJ, 2003. Drug companies want to inform patients. BMJ, 326, 1286.

60. Watson, Rory, 2003. EU health ministers reject proposal for limited direct to consumer advertising. BMJ, 326, 1284.

61. Watson, R., 2006. Cancer group denies company funding will influence its agenda. BMJ, 333, 874.

62. Mayor, Susan, 2002. GMC issues new guidance on clinical research. BMJ, 324,384.

63. Marwick, Charles, 2002. US tackles drug company gifts to doctors. BMJ, 325, 795.

64. Mosconi, Paola, 2003. Declaration of competing interests is rare in Italian breast cancer associations. BMJ, 327, 344.

65. Herxheimer, A., 2003. Relationships between the pharmaceutical industry and patients’ organisations. BMJ, 326, 1208–1210.

66. Hirst, J., 2003. Charities and patient groups should declare interests. BMJ, 326, 1211.

67. Clark, Jocalyn, 2003. A hot flush for Big Pharma. BMJ, 327, 400.

68. Writing Group for the Women’s Health Initiative Investigators, 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288, 321–333.

69. The Times, 15 December 2006.

70. Moynihan, Ray, 2003. US seniors group attacks pharmaceutical industry ‘fronts’. BMJ, 326, 351.

71. Cho, E, and others, 2006. Red meat intake and risk of breast cancer among premenopausal women. Archives of International Medicine, 166, 2253–2259.

72. Lenzer, Jeanne, 2002. The operation was a success (but the patient died). BMJ, 325, 664.

73. Moynihan, Ray, 2003. Blurring the boundaries. BMJ. 326, 1094.

74. The selling of a wonder drug. The Guardian, 29 March 2006.

75. http://en.wikipedia.org/wiki/Trastuzumab.

76. Barrett, A. and others, 2006. How much will Herceptin really cost? BMJ, 333, 118–120.

77. Bartlett, Christopher, Sterne, Jonathan and Egger, Matthias, 2002. What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ, 325,

81.

78. http://www.madnessmansion.com/!!jimkc/txt/ambulanc.txt/ http://www.public.asu.edu/!! tadams2/Quotes/Ambulance

79. www.cancersupportinternational.com